Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
Issued Date
2023-07-29
Resource Type
eISSN
20411723
Scopus ID
2-s2.0-85166029349
Pubmed ID
37516752
Journal Title
Nature communications
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature communications Vol.14 No.1 (2023) , 4568
Suggested Citation
Nguyen T.D., Gao B., Amaratunga C., Dhorda M., Tran T.N.A., White N.J., Dondorp A.M., Boni M.F., Aguas R. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nature communications Vol.14 No.1 (2023) , 4568. doi:10.1038/s41467-023-39914-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/88204
Title
Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
Other Contributor(s)
Abstract
Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas of multidrug-resistant malaria. Whether early TACT adoption could delay the emergence and spread of antimalarial drug resistance is a question of vital importance. Using two independent individual-based models of Plasmodium falciparum epidemiology and evolution, we evaluated whether introduction of either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower long-term artemisinin-resistance levels and treatment failure rates compared with continued ACT use. We show that introduction of TACTs could significantly delay the emergence and spread of artemisinin resistance and treatment failure, extending the useful therapeutic life of current antimalarial drugs, and improving the chances of malaria elimination. We conclude that immediate introduction of TACTs should be considered by policy makers in areas of emerging artemisinin resistance.